AC
PDSB icon

Armistice Capital’s PDS Biotechnology PDSB Stock Holding History

Armistice Capital’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$105K Sell
173,605
-2,660,901
-94% -$2M ﹤0.01% 245
2025
Q4 		$2.18M Buy
+2,834,506
New +$2.56M 0.03% 158
2025
Q3 		– Sell
-2,236,000
Closed -$2.97M – 374
2025
Q2 		$2.97M Sell
2,236,000
-2,183,000
-49% -$2.96M 0.05% 120
2025
Q1 		$5.26M Buy
+4,419,000
New +$6.29M 0.08% 112

Other funds holding PDSB

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Armistice Capital's PDSB Position: Q1 2026 in Review

Armistice Capital reduced its PDS Biotechnology (PDSB) stake by 94% in Q1 2026, selling an estimated $2M and leaving 173,605 shares worth $105K. The position accounts for ﹤0.01% of the portfolio, ranked #245.

Armistice Capital first reported a position in PDSB in Q1 2025 and has held it in 4 quarters since. The position peaked at $5.26M in Q1 2025. 41 funds tracked by Wall St. Rank hold PDSB as of Q1 2026.

  • Armistice Capital held 173,605 shares of PDS Biotechnology worth $105K as of Q1 2026.
  • Armistice Capital sold 2,660,901 PDS Biotechnology shares in Q1 2026, an estimated $2M.
  • PDS Biotechnology made up ﹤0.01% of Armistice Capital's portfolio in Q1 2026, its #245 holding.
  • Armistice Capital first reported a position in PDS Biotechnology in Q1 2025 and has held it in 4 quarters since.
  • Armistice Capital's PDS Biotechnology position peaked at $5.26M in Q1 2025.
  • 41 funds tracked by Wall St. Rank held PDS Biotechnology as of Q1 2026.

Based on Armistice Capital's 13F filing for Q1 2026, filed 15 May 2026.